Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
CA 2291750 A1 · Owner: Myers, Michael R. · Inventors: Myers, Michael R.; Spada, Alfred P.; He, Wei
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity to , pharmaceutical compositions comprising these compounds and to the use of , these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 28, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 28, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 28, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.